Search - tctmd.com

Displaying 41 - 60 of 392

Sort: Relevancy | Date

News Conference News AHA 2019

Early Data Favorable for New RNAi Therapies to Reduce Triglycerides

Caitlin E. Cox

November 19, 2019

News Conference News AHA 2019

Inclisiran in FH: Safe, Cuts LDL in This Challenging Group

Yael L. Maxwell

November 19, 2019

News Conference News AHA 2019

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

Yael L. Maxwell

November 16, 2019

News Conference News AHA 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

Shelley Wood

November 11, 2019

Presentation TCT 2019

What is the Role of the Interventional Cardiologist in Lipid Management?

Presenter: Wolfgang Koenig

September 28, 2019

Presentation TCT 2019

The State of The Art in LDL-C Lowering: Urgent Needs and Unmet Opportunities

Presenter: R. Wright

September 28, 2019

Presentation TCT 2019

The Angiogram: Charting the Course for Effective Lipid Management

Presenter: Ori Ben-Yehuda

September 28, 2019

News Industry News

Abbott Launches World's First Pivotal Trial To Test New Approach For Repairing Leaky Tricuspid Heart Valves

September 05, 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Published Cohort

News Conference News ESC 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Yael L. Maxwell

September 03, 2019

News Daily News

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Todd Neale

August 23, 2019

News Daily News

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

Michael O'Riordan

July 30, 2019

News Industry News

Abbott Receives U.S. Approval Of Next-Generation Mitraclip™, Bringing New Enhancements To Abbott's Leading Mitraclip Platform

July 15, 2019

News Industry News

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

June 26, 2019

News Conference News EAS 2019

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Michael O'Riordan

June 04, 2019

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

News Features

Top News in Prevention: 2018

Michael O'Riordan

December 28, 2018

News Daily News

Race May Be a Proxy for Many Disparities in CVD Treatment, Outcomes

Yael L. Maxwell

November 07, 2018

News Daily News

FDA: Contaminated Irbesartan Now Under Voluntary Recall

Michael O'Riordan

October 31, 2018

News Conference News ESC 2018

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

Shelley Wood

August 28, 2018

News Daily News

Valsartan Recall Expanded by FDA and European Medicines Agency

Shelley Wood

August 10, 2018

Advertisement

Early Data Favorable for New RNAi Therapies to Reduce Triglycerides

Inclisiran in FH: Safe, Cuts LDL in This Challenging Group

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

What is the Role of the Interventional Cardiologist in Lipid Management?

The State of The Art in LDL-C Lowering: Urgent Needs and Unmet Opportunities

The Angiogram: Charting the Course for Effective Lipid Management

Abbott Launches World's First Pivotal Trial To Test New Approach For Repairing Leaky Tricuspid Heart Valves

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

Abbott Receives U.S. Approval Of Next-Generation Mitraclip™, Bringing New Enhancements To Abbott's Leading Mitraclip Platform

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Top News in Prevention: 2018

Race May Be a Proxy for Many Disparities in CVD Treatment, Outcomes

FDA: Contaminated Irbesartan Now Under Voluntary Recall

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

Valsartan Recall Expanded by FDA and European Medicines Agency

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content